This invention provides an isolated mammalian nucleic acid molecule
encoding a PAK4 serine/threonine kinase. This invention provides an
isolated nucleic acid molecule encoding a mutant homolog of the mammalian
PAK4 serine/threonine kinase whose amino acid sequence is set forth in
FIG. 1A (SEQ ID NO: 2). This invention provides a fusion protein
comprising a PAK4 serine/threonine kinase or a fragment thereof and a
second peptide. This invention provides a purified mammalian PAK4
serine/threonine kinase. This invention provides a protein comprising
substantially the amino acid sequence set forth in FIG. 1A. This
invention provides a monoclonal antibody directed to an epitope of a PAK4
serine/threonine kinase. This invention provides a method of inhibiting
PAK4 function comprising administering a ligand comprising an amino acid
domain which binds to a GTP binding protein so as to inhibit binding of
the GTP binding protein to PAK4. This invention provides a method of
inhibiting PAK4 function comprising administering a ligand which binds to
the GTP binding domain of PAK4 so as to inhibit PAK4 binding to a GTP
binding protein. This invention provides a method of inhibiting PAK4
serine/threonine kinase function comprising administering a ligand which
blocks an ATP binding domain so as to inhibit PAK4 serine/threonine
kinase function. This invention provides a method of inhibiting growth of
a tumor cell comprising blocking Cdc42Hs by administering a ligand
capable of binding to a Cdc42Hs binding site of a PAK4 serine/threonine
kinase.